TherapeuticsMD, Inc. (NASDAQ:TXMD) Sees Significant Decrease in Short Interest

TherapeuticsMD, Inc. (NASDAQ:TXMD) was the recipient of a significant drop in short interest during the month of January. As of January 31st, there was short interest totalling 173,800 shares, a drop of 27.6% from the January 15th total of 240,200 shares. Approximately 1.5% of the shares of the company are short sold. Based on an average trading volume of 289,900 shares, the days-to-cover ratio is presently 0.6 days.

TherapeuticsMD Price Performance

NASDAQ:TXMD remained flat at $1.03 on Friday. The company’s stock had a trading volume of 36,898 shares, compared to its average volume of 62,033. TherapeuticsMD has a 12-month low of $0.70 and a 12-month high of $2.75. The firm has a 50 day moving average of $1.10 and a two-hundred day moving average of $1.43.

TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.05) earnings per share for the quarter. TherapeuticsMD had a negative net margin of 207.77% and a negative return on equity of 14.08%. The business had revenue of $0.55 million during the quarter.

Analyst Ratings Changes

Separately, StockNews.com began coverage on shares of TherapeuticsMD in a research note on Tuesday, January 14th. They set a “hold” rating on the stock.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.